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CHEMICAL CARCINOGENESIS AND EXPERIMENTAL
CHEMOTHERAPY OF CANCER*
E. BOYLAND
A great paradox in our knowledge of cancer lies in the fact that
substances which induce tumours are also able to inhibit the growth
of normal and of malignant tissues. At the present stavae in the search
for therapeutic agents for cancer it appears worth while to work for
limited objectives in the way of measures which will restrict or inhibit
malignant growths. The eventual aim will be, of course, the curative
agent, which will destroy cancer cells or perhaps change them back
into normal cells. Now the inhibition of tumour growth which can be
used as the basis for palliative treatment can be attained experimentally
and clinically with some carcinogenic compounds. These inhibitory
agents are worth study for their possible immediate clinical value, for
information which they may give as to the nature of tumours, and for
the fact that investigation of such substances might lead to the discovery
of more effective therapeutic agents. The mechanism of the action of
carcinogens is therefore of value both for the study of carcinogenesis
and of inhibition, as further knowledge of carcinogenesis may lead to
means of preventing cancer while inhibitory effects may be of value in
treatment.
The paradox is illustrated by the action of cestrogens in the study
of which Dr. Allen made such brilliant contributions to our knowledge.
The natural and synthetic cestrogens are able to induce tumours in
animals which are deficient in the hormone but have other factors
necessary for the development of the disease. Thus cestrogens are
carcinogenic to male mice of strains in which mammary cancer normally
occurs in the females. Huggins"8 has shown that cestrogens are effective
in treatment of cancer of the prostate. Such treatment is not really
curative, but rather palliative. This treatment serves as a standard at
the present time; and if any treatment of malignant disease is as
effective as the cestrogen therapy of prostatic cancer, then, it seems
worthy of attention.
* From the Chester Beatty Research Institute, The Royal Cancer Hospital (Free),
London, S.W.3. Presented as the Edgar Allen Memorial Lecture at Yale University on
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The cestrogens form one group of carcinogenic agents, but I wish
to speak about other groups. There are a number of nitrogenous carcino-
genic agents such as azo dyes like butter yellow, certain basic stilbene
derivatives such as 4-dimethylaminostilbene, polycyclic amines like 2-
acetylaminofluorene, and heterocyclic compounds like 3:4:5:6-
dibenzcarbazole. These nitrogenous carcinogens have the power of in-
ducing cancer at sites remote from the original point of application of
the drug. The fundamental mechanism of these compounds, however, is
probably similar to that of the carcinogenic hydrocarbons, which have
primarily a local action.
Carcinogenic hydrocarbons
The discovery of the first carcinogenic hydrocarbons by Sir Ernest
Kennaway and his colleagues showed that important biological changes
such as the conversion of normal into malignant cells were brought
about by what appeared to be rather inert substances, which were in-
soluble in water. The chemical inertness and insolubility in water
suggested thatthesubstancesmightact in thelipoidphaseofcells orwere
converted into biologically active derivatives as the water insoluble
carotene is converted into the active vitamin A protein complexes such
as visual purple in the body. Alternatively they may be absorbed to
some essential cell constituent. The problem of the reactivity of
carcinogenic hydrocarbons has completely changed since the early
thirties when the chemical inactivity of the substances seemed remark-
able. Now, on the contrary, so many reactions are known that the
difficulty is to decide which, if indeed any, are of biological importance.
Professor Cook showed that the carcinogenic hydrocarbons could be
oxidised to quinones by vigorous oxidising agents, but such quinones
are not carinogenic (Barry et al.1). The introduction of polar
groups, such as phenolic hydroxyl groups or carboxyl groups,
invariably leads to the destruction of thecarcinogenic activity. Less polar
groups such as methoxyl groups do not destroy the ability to produce
tumours, and non-polar substituents such as methyl may enhance
carcinogenic power if they occupy the right positions.
Many carcinogenic compounds are fluorescent and it is not possible
to say how fluorescence is related to carcinogenic power, but changes in
the molecule which reduce the fluorescence, destroy the carcinogenic
activity. As is well known, the hypothesis that fluorescence of tar con-
stituents is associated with carcinogenicity was extremely valuable, and
the use of this physical property as a clue led to the isolation of
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benzpyrene from pitch and to the synthesis of active derivatives of
1:2-benzanthracene. Although fluorescence may be an important factor
in carcinogenesis, some carcinogenic agents other than hydrocarbons are
not fluorescent. Fluorescent substances are step-down transformers of
radiant energy and it is possible that the agents act by converting some
kind of radiant energy within the tissues into energy forms which are
carcinogenic in the way that radiations such as X-rays are carcinogenic.
An alternative hypothesis that carcinogenic compounds and also radia-
tions produce some common condition leading to the induction of
tumours seems a more plausible explanation for the similarity in action
of the two groups of agents.
The carcinogenic hydrocarbons and the carcinogenic compounds
containing nitrogen or sulphur such as the carbazole, acridine, and
thiophanthrene derivatives are all flat planar molecules. Modifications
of the structure which change the planar nature lead to loss of activity.
The carcinogenic trans aminostilbenes (Haddow and Kon"7) are also
long flat molecules: the cis isomers which are not planar are inactive.
Thus we have indications that large carcinogenic molecules should be
flat and long, shaped rather like an irregularly shaped roofing tile or
slate. Themolecules mustnot betoo large. Two hexacyclic hydrocarbons
1:2:3:4- and 3:4:8:9-dibenzpyrene are carcinogenic but larger mole-
cules are inert. The shape of the molecule may vary considerably as
there are hundreds of carcinogenic substances. The chemical reactivity
ofthe flatmolecule maybemore important forcarcinogenesis than is the
shapeofthemolecule. Haddow10 haspointed outhowmanycarcinogenic
compounds such as 3:4-benzpyrene and 1:2:7:8-dibenzfluorene in-
74 corporate a trans
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FIG. 1. Isomeric dimethylthiophanthrene derivatives. Compounds 1, has suggested that 2, and 4 which have phenanthrene structures are carcinogenic, whil.e e compound 3 which has no phenanthrene structure is not carcinogenic. tne essential feature
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of the carcinogenic molecule is the phenanthrene type bridge or an
equivalent chemical structure. In testing this hypothesis isomeric
thiophanthrene derivatives were made resembling 9:10-dimethyl-1:2-
benzanthracene. The active compounds could be represented as having a
phenanthrene type of structure, while an inactive isomer did not contain
a phenanthrene type double bond (see Fig. 1).
The electrondistributionin carcinogenicmolecules
French workers have investigated the carcinogenic substances from
thepointofviewof electron distribution and chemical reactivity, follow-
ing the earlier work of Otto Schmidt. Thus A. and B. Pullman have
investigated thedistribution ofelectrons in the molecules of carcinogenic
compounds by the methods of quantum mechanics developed by Pro-
fessorPauling. Byconsideration of thedifferent possible resonance forms
of a number of polycyclic compounds, A. and B. Pullman2" have cal-
culated the densities of free electrons at different parts of the molecules.
The mean electron density of an area of the molecule depends upon the
electrons attached to the bond and the electrons around the atoms at
each end of the bond. In the non-carcinogenic hydrocarbons such as
anthracene, the high electron density areas of the meso carbon atoms
and of the reactive double bonds do not over-lap so that there is no
region approximat-
-. l~ing the size of a car-
bon-carbon bond
with a particularly
highelectrondensity
ANTHRACENE PHENANTHRENE (see Fig. 2). In
phenanthrene, be-
cause the electron-
rich carbon atoms
are joined by an
electron-rich bond,
the density of the
region ishigher than
K.RCCION KROECION N any similar region
ELECTRON DENSITY 54
- 293 DC in anthracene, but is
not so high as in the 3.4. BENZPHENANTHRENE CHRYSENE carcinogenic hydro-
FIG. 2. The representation of densities of free electrons at bonds and carbons. The region around atoms in polycyclic compounds. of high electron
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chargehasbeencalledtheK region by the Pullmans, and in carcinogenic
hydrocarbons the calculated mean electron charge of the area has been
found to be between 1.29e and 1.35e in the examples for which the
laborious calculations have been made. There is close correlation be-
tween carcinogenic power and electron
Xe~~~~~~~~~~~z
CH3 , XC
CH, CH,
ELECTRON,
CARCINOGENICITY DENSITY of
K REGION
- 1.283
+ 1.294
+ 1.298
4- + 1.296
+++ 1.307
CHC H, 1.330
CH3
CH,
FIG. 3. The relation between carcinogenicity and density
of electrons in the K region of a series of derivatives of
1:2-benzanthracene.
The hypothesis that reactiveness of thi,
density of the K region.
This is shown in the 1:2-
benzanthracene series in
Fig. 3. The deductions still
depend upon theoretical
considerations. If some
quantitative chemical reac-
tion could be found which
depended upon the activity
of this region, the data
might be placed on a less
theoretical basis. In many
casesofcomplex molecules,
determination by chemical
reactivity would be very
much more rapid than by
the present method of cal-
culation. Known reactions
which do involve this
phenanthrene bond are the
catalytic hydrogenation re-
action described by Fieser
and Hershberg'4 and the
oxidation with osmic acid
in thepresence ofpyridine,
which has been studied by
Cook and Schoental.10
s K region is of importance
is supported by three different lines of evidence:
(1) The theoretical calculations of the French workers, suggesting
that carcinogenicity varies with the nature of the K region.
(2) The view of Sir Robert Robinson that an activated phenan-
threne double bond may be essential.
(3) The investigations of chemical reactivity of carcinogens which
have shown that the atoms of this K region react preferentially in
catalytic hydrogenation and in the oxidation to diols by osmic acid.
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These reactions are addition reactions to the phenanthrene double bond
or K region, and such reactions are much more likely to occur in the
body than are substitution reactions.
Metabolism ofhydrocarbons
Many carcinogenic substances thus have two chemically reactive
regions, the meso carbon atoms and the bond corresponding to the phenanthrene bridge. The active meso carbon atoms are not essential
for carcinogenic activity as the carcinogenic benzphenanthrenes do not have meso carbon atoms. Studies in metabolism of carcinogenic com-
pounds, however, indicate that reactions in other positions than the Kregionormesopositionscanoccurinthebody. Aromatichydrocarbons
of less complexity than the carcinogens are known to undergo two types of reaction in the animal body. One type of reaction consisting of com- bination with the sulphydryl group of cysteine has been shown to occur
with simple hydrocarbons, benzene, naphthalene, and anthracene, which
are excreted as mercapturic acids. That carcinogenic compounds may combine with sulphydryl groups is suggested by the experiments of Crabtree,"' in which the carcinogenic action of hydrocarbons was neutralised by reagents known to react with sulphydryl compounds such as bromobenzene and maleic acid. There is no evidence that carcinogenic hydrocarbons are excreted combined with cysteine as mercapturic acids and no direct evidence that they combine with sulphydryl groups of proteins. Fieser has suggested that 3:4-benzpyrene possibly combines with the sulphur linkage of a protein through the chemically reactive 5 position. But combination might occur by addition to the 6:7 positions.
The main known metabolic path of hydrocarbons and nitrogenous carcinogens is hydroxylation. In the metabolism of naphthalene, 3,25 anthracene,6 and phenanthrene, the products have been shown to be diols or dihydroxy dihydro derivatives. This metabolic process has been called perhydroxylation because it involves the addition of the atoms of hydrogen peroxide to the molecule. The aromatic character of the ring
to which the hydroxyl groups are added is destroyed as a result of the addition to the double bond. All these diols are unstable in acid solution,
when they lose water to be converted into phenols which are again aromatic incharacter. Thephenolicmetabolites whichhave been isolated after dosing animals with hydrocarbons or with other aromatic com- pounds are probably artefacts or decomposition products arising from furtherchange ofthe diols. In the cases ofcarcinogenic compounds, only
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phenolic metabolites have so far been actually isolated and definitely
characterised. Thefirstofthesephenolstobeisolated werethedihydroxy-
phenols produced from 1:2:5:6-dibenzanthracene. Dobriner, Rhoads,
and Lavin13 isolated a phenol from the urine of rats and mice injected
with 1:2:5:6-dibenzanthracene which was identical with 4':8'-dihy-
droxy-1:2:5:6-dibenzanthracene synthesised by Cason and Fieser.' The
metabolite produced by rabbits7 is different from that of rats and mice,
but it is a dihydroxy compound in which we still do not know the
position of the entering groups.
I think that we are justified in assuming that the phenolic 4':8'-
dihydroxy-1:2:5:6-dibenzanthracene is formed from a labile 3':4':7':8'-
tetrahydroxy-3':4':7':8'-tetrahydro-1:2:5:6-dibenzanthracene analogous
to the diols produced
PHENOL ISOLATED. PROBABLE NATURAL r * s
DIOL fromsimpleraromaticcom- N ~~~~HoN pounds (Fig. 4). Even
No Ho7 without this assumption
OH Otl the metabolite is remark-
DIN.2 OH able in that the hydroxyl DOBRINER,RHOADS cnd LAVIN.1942. BOYLAND et 941. groups are mtroduced not
CH fh CH nIOH into the mesopositions nor
CH CHOH into the phenanthrene
QOc9OH bridge or K region. This
CH3 CH3 means that the only bio-
DICKENS ond WEILMALHERBE. 145. *
c chemical change which we
know to take place occurs
OH in positions other than the
meso carbon atoms or the
BERENSUm etd s43 K region.
FIG. 4. The structure of metabolites of carcinogenic
hydrocarbons which have been isolated, and the possible This hydroxylation In
d hdoxZhydro-derivatives or diols to which they are** r . ..
related. positions of tertiary activity
is also shown by the pro-
duction of4'-hydroxy-1 :2-benzanthracene from 1:2-benzanthracene and
of 4'-hydroxy-9:10-dimethyl-1:2-benzanthracene from the highly car-
cinogenic 9:10-dimethyl-1:2-benzanthracene by rats. The 3:4-benz-
pyrene molecule is more complicated and the metabolism more difficult
to interpret on the basis of reactivity, since a mixture of 8 and 10
benzpyrenols is excreted by both rats and rabbits treated with 3:4-
benzpyrene (Berenblum et al.2). But in neither of the products has the
hydroxyl group entered the most reactive 5 position, the K region, or
the phenanthrene bridge position.
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Such of these phenolic metabolism products as have been tested are
themselves non-carcinogenic but the methylated benzpyrenols or
methoxy benzpyrene derivatives are carcinogenic. These non-carcino-
genic phenols are probably products formed from non-phenolic diols.
Weigert26 studied benzpyrene metabolism in mice and, although most
of the products were not actually isolated, they were identified or
characterised by means of chemical properties and absorption spectra
andfluorescent spectraofminute amountsofmaterial. Whenbenzpyrene
is injected into intact mice or painted on the detached skin of mice, it
is first converted into a product with a blue fluorescence different from
that of benzpyrene itself. Such a derivative was first described by Pea-
cock20 as being present in the bile of animals injected with benzpyrene,
and was called BPX. When the BPX passes down the alimentary tract
below the ileocaecal valve, it changes into products with greenish-blue
fluorescence. The greenish-blue fluorescing material contains two
phenolic substances, BPF1 and BPF2, which are probably related to 8-
or 10-hydroxy-benzpyrene. Weigert found that BPX contained two sub-
stances and differentiated them as BPX1 and BPX2. These metabolic
changes are indicated in a scheme in Fig. 5.
to H Both the
7 9 7 7 7OH OH BPX, andBPX2
OH
I ~~~ ~1 ,~~~ ~ 7~ derivatives are
water soluble
BENZPYRENE B P X BENZPYRENOL
OH
OH 7 7
H
OR OR
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FIG. 5. Scheme showing the metabolism of the hydrocarbon benzpyrene
through the diol BPX to the phenol BPF.
and formation
of one of them
maybe adetoxi-
cation process.
They differ in
their absorption
spectra and in
the fact that
BPX2 is less
soluble than is
BPX1 in benzene or toluene. The data would fit in with the idea that
BPX1 is a diol and BPX2 its glycuronide. It was suggested that BPX2
was possibly formed under conditions in which tumour production was
slow and therefore could be considered as a detoxication process, but
the known facts are insufficient to determine whether this is the case
or not.
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That the blue fluorescing BPX is a diol is probable because of the
following facts. First, the compound BPX is easily converted by acid
hydrolysis to the phenolic benzpyrenol, in the same way that the
naphthalene diol is converted to the corresponding naphthol. Second,
the ultraviolet absorption of BPX shows much less fine structure and is
mainly at shorter wave-lengths than that of the corresponding known
benzpyrenol. The firsttrough of the absorption is 150 A farther into the
ultraviolet than that of the corresponding phenol. The absorption of
the naphthalene diol shows analogous differences from that of naphthol.
Third, BPX is soluble in water but the fluorescence is unchanged by
acid and alkali so that the hydroxyl groups have no phenolic properties.
The fluorescence of BPF or benzpyrenol is changed by alkali because of
the phenolic nature of the hydroxyl group.
We are therefore probably justified in considering this relation of
the metabolic products of benzpyrene as a reasonable hypothesis. It is,
however, possible that metabolism of carcinogens by perhydroxylation
is a detoxication and is not directly associated with the carcinogenic
change, but I think the change is essential for carcinogenesis, and the
dihydroxy dihydro derivative or the energy changes concerned with
its formation or breakdown are the proximate causes of carcinogenesis
and I will try to summarise the experimental evidence on the subject.
The conversion of carcinogens to water-soluble diols occurs in
mouse skin. If benzpyrene is painted on the excised skin of a recently
killed mouse the benzpyrene is changed into BPX, and under such
conditions as much as 80 per cent of a small amount (say, 5 KAg. per
cm.2 of skin) of benzpyrene can be transformed into BPX after in-
cubation for 6 hours in Ringer solution.- Under these conditions the
BPX does not diffuse into the Ringer solution but can be extracted from
the tissue with wet acetone. This suggests that the BPX is combined
with tissue constituents in the surviving cells. Analogous changes occur
in most of the body tissues of mice. If a suspension of benzpyrene is
injected intravenously, it is stored in many of the organs, such as liver,
lung, kidney, and adipose tissue, and then metabolised and excreted. In
some experiments from 60 per cent to 80 per cent of the injected
benzpyrene has been accounted for as BPX.
Conditions which increase the carcinogenic action of benzpyrene
increase also the rate of excretion, as was shown clearly by experiments
of Dickens and Weil-Malherbe."2 When benzpyrene dissolved in
tricaprylin containing 3 per cent cholesterol was injected into mice,
it was more rapidly excreted and produced tumours more
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FIG. 6. The incidence of local tmmours in mice following
of 300 mg. of 3:4-benzpyrene in different solvents.
TRICAPRYLIN with
>CEPHALIN 3
TRICAPRYLIN TRICAPRYLIN -K
+ CHOLESTEROL ALONE
300
100
BP(ju )
30
10
0 2 4 6 8 0 12'
WEEKS
RATE OF DISAPPEARANCE OF BENZPYRENF
FIG. 7. Elimination of 300 mg. of 3:4-benzpyrene from
mice after subcutaneous injection in different solvents.
rapidlythanwhen it
was injected in tri-
caprylinalone (Figs.
6 and 7). Addition
of cephalin and
lecithin to the tri-
caprylin solution of
benzpyrene de-
creased the rate of
N with metabolism of the
.CITHIN carcinogen and in-
creasedthemeanin-
duction time of the
tumours.
The process of
diol formation is
o probably a meta-
bolic process which
i.j. onnormally involves
ijection the usual body con-
stituents. When we
inject synthetic materials
such as naphthalene or car-
cinogenic hydrocarbons, we
present the cell enzymes
with a substrate which re-
sembles some normal tissue
constituents sufficiently
closelyfor itto bedealtwith
through the usual channels.
Theknowncommonnatural
substances resembling the
aromatic hydrocarbons are
phenyl alanine and the
steroids. It is possible that
injection of cholesterol
would increase the power of
the tissue to metabolise steroids by a mechanism analogous to the pro-
duction of adaptive enzymes and with this a concomitant ability to
metabolise hydrocarbons.
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Some preparations of mouse fat have an effect similar to that of
cephalin or lecithin in reducing both carcinogenesis and excretion of
benzpyrene. On the other hand, croton oil, which Mottram and
Berenblum have investigated, accelerates metabolism of carcinogens
and carcinogenesis. In all the known cases, acceleration of metabolism
and of carcinogenesis go together.
Another argument in favour of the hypothesis I wish to put for-
ward depends upon the relation of the stereo isomers of the diols pro-
duced by different species and the difference in response to carcinogens.
If a cold solution of 1:2:5:6-dibenzanthracene is injected into mice or
rats itinduces tumours in most cases at the site ofinjection, but the same
material injected into rabbits does not produce tumours at the site of
injection. Some other carcinogens will produce local tumours in rabbits,
but rabbits are undoubtedly more resistant to carcinogens than are rats
or mice. Now when naphthalene and anthracene are injected into rats
and rabbits they aremetabolished todiols which contain two asymmetric
carbon atoms. The spacial configurations of the diols produced are
different in the twospecies. In the case ofnaphthalene, the ratproduct is
lavo-rotatory andthe rabbitproduct isdextro-rotatory.' Chemical exami-
nation of the compounds, and particularly their reaction rate with
lead tetra-acetate, indicates that the hydroxyl groups in both compounds
have the trans configuration.8 The rat and rabbit products appear to be
optical antipodes or mirror images of the same compound. The products
from anthracene which I have investigated with Dr. Levi' and Dr.
Shoppee,8 and phenanthrene, which has been studied by Dr. Wolf and
myself, are not so simple, but the metabolic products of the species
showing differences in optical activity have been isolated. Extension of
these results to carcinogens would suggest that rabbits convert a
carcinogenic hydrocarbon into a diol with a dextro configuration which
is not carcinogenic, while rats and mice convert the hydrocarbons into
derivatives of the lavo series which are carcinogenic.
An analogous species difference in carcinogenicity and metabolism
is found with ,B-naphthylamine. When given to dogs 3-naphthylamine
is excreted as the sulphate of 2-amino-1-naphthol, and f-naphthylamine
induces cancer of the bladder in dogs. In other species, including rats
and rabbits, no bladder tumours are induced and the excretion product
is 2-acetylamino-6-hydroxy-naphthalene.
The formation of a diol involves the conversion of an aromatic
ring into a non-aromatic or less unsaturated ring. The fact that the
hydroxyl groupsenterinpositionsotherthan thoseofthe activeK region
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indicates that the K region is probably combined with some tissue
constituent. Now the combination through the K region may be due to
substitution, in which case the ring containing the K region or phenan-
threne double bond would remain aromatic. The bond of the K region,
however, has ethylenic character which would favour addition rather
than substitution. Also, there are the examples of two carcinogens 4:9-
dimethyl-1 :2-benzanthracene and 4:10-dimethyl-1 :2-benzanthracene in
both of which one hydrogen of the K region is substituted by a methyl
group. In such a compound, substitution could only occur in one of the
positions. The known examples of reactivity of the K region are of
addition reactions such as the catalytic hydrogenation and the perhy-
droxylation byosmic acid.
Whatever the combination on the atoms of the K region, it appears
to beof a labile nature as only the free diol has been isolated and not the
complexes. One possibility is that the partial saturation of the ring ad-
joining the K region changes the affinity of the bond so that the free
diol is released. Although a highly active K region is necessary for
carcinogenesis, it is obviously not required for the conversion of a
hydrocarbon such as naphthalene into a diol. This suggests that the
linkage of a carcinogen through the K region is stronger than is the
HYPOTHETICAL CARCINOGEN
COMPLEXES.
H
OH
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FIG. 8. Hypothetical tissue carcinogen com-
plexes which may be the cause of inhibition of
growth and carcinogenesis.
linkage of a substrate to an
enzyme; but it may be similar to
linkages of that kind. The type of
complex postulated is shown in
Fig. 8. These complexes may be
analogous to the protein-vitamin
A compounds of normal cells.
At one stage in the process,
therefore, the carcinogen is held by
addition to the K region double
bond while other rings may be
"de-aromatised" by diol formation.
In the case of 1:2:5:6-dibenzan-
thracene, of the original five aro-
matic rings two may be converted
into dihydroxy dihydro benzene
rings while the K region rings
are converted into substituted
cyclohexadiene ordihydro benzene
rings. If both the K regions did
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this then only one aromatic ring would remain, and that is not a typical
benzene ring as it originally contained two meso atoms.
If these changes do occur, then the products with partially saturated
rings would approach the naturally occurring steroids in their nature.
The converse process to this, namely, that of aromatisation, probably
occurs in the body also. Some years ago Bernhard found that when
cyclohexane carboxylic acid was administered to animals it was excreted
as benzoic acid. Recently Dickens has been able to follow the same
change in isolated liver tissue. Cholesterol is certainly co-carcinogenic
and may indeed be carcinogenic. For its carcinogenic action it would
probably be changed into an unsaturated derivative by removal of
hydrogen and possibly of angular methyl groups. The unsaturated or
ethylenic character of the carcinogen is probably necessary to attain
planarity and chemical reactivity of the K region, so that the molecule
can become attached to the essential active constituent of the changing
tissue for some considerable time.
Carcinogenesis andinhibition ofgrowth
Whatever the biochemical mechanism, it seems probable that one
stage is due to growth inhibitory action of the carcinogen. Haddow has
shown that carcinogens inhibit body growth and has described how the
study of this inhibitory power led to the discovery of a new class of
carcinogens, the aminostilbene derivatives. The aminostilbenes are
remarkable growth-inhibitory compounds and produce tumours in a
wide variety of tissues. Another carcinogen which biochemists would
consider as a general inhibitor rather than as a stimulator is urethane.
Urethane inhibits many enzymes, stops cell division in a way similar to
radiations and thechloroethylamine drugs,and induces cancerofthe lung
in rats and mice. These facts do indeed suggest that the carcinogenic
process involves an inhibitory stage and it may be in an effort to over-
come such inhibition that the tumour cell arises. The type of structure
suggested is presumably that responsible for the inhibition. Inhibitory
processes of this kind seem to be associated with genetic instability.
Urethane and the chloroethylamines like radiations, inhibit growth and
also increase the incidence of mutations in Drosophila and other species,
and Strong24 has shown that carcinogens increase the rate of genetic
changes in mice. The linkage between the two phenomena of growth
inhibition andgenetic instability suggests thatthe underlyingmechanism
may involve the same cell constituents. The genetically stable form of
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cells may require a dynamic equilibrium with the momentum of growth
and division conferring stability. With inhibition the chance of pro-
duction of tumours or mutations is increased. The prolonged presence
of the carcinogenic complex may increase the difficulties of cell division
so that the risk of the accident of a somatic mutation occurring at cell
division is increased. A proportion of these mutations may give rise to
tumours.
The carcinogenic aminostilbenes
The aminostilbenes which have been investigated by Haddow, Kon,
and theircolleagues'7 areparticularly interesting from the point of view
of carcinogenesis and inhibition as their inhibitory properties were dis-
covered first. Having been shown to be effective inhibitors of growth,
they were tested for carcinogenic action and were found to produce
tumours in many parts of the body in a way similar to the action of
2-acetylaminofluorene.
The simplestcompound of this group is p-aminostilbene which itself
is rather toxic, producing methaemoglobinemia. Substitution of the
amino group as in dimethylaminostilbene gave a compound of lower
toxicity which was about ten times as effective as carcinogenic hydro-
carbons in inhibiting the growth of grafted tumours in rats and mice.
The activity was further enhanced by introduction of a methyl group or
a chlorine group in the 2' position. If such substituents or a hydroxyl
group were placed in the para or 4' position activity was lost. This
effect is remarkable in that metabolic tudies indicate that 4-dimethyl-
aminostilbene appears to be converted in the body to 4-amino-4'-
hydroxystilbene.
The 2'-methyl and 2'chloro-4-dimethyl-aminostilbenes have been
used in a few clinical trials on cancer patients. The problems of admin-
istration have not yet been entirely overcome and results comparable
withthoseobtainedbytreatmentofcanceroftheprostatewithcestrogens
arestill tobeobtained. Recently Elson has found that the aminostilbenes
and carcinogenic hydrocarbons are much more effective in inhibiting
growth when given to animals maintained on a low protein diet than
when given to those on a normal or high protein diet.
Urethane
Another carcinogen which has been used in therapy of malignant
disease is urethane or ethyl carbamate. This simple and rather in-
effective narcotic is able to induce cancer of the lung in rats and mice
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and is an inhibitor of cell division and mitosis. Although the effect of
urethane on growing transplanted tumours is not very great, the drug
has considerable effect in leukxmia and has been used with success
as an alternative to radiation in treatment of cases of both lymphatic
and myeloid leukoemia." Patients are given 3 or 4 gm. ethyl carbamate
per day and at this level the drug does not appear to have even a
soporific action. Urethane inhibits cell division in the early stages and
causes "chromosome breaks" in the same way as do radiations. It there-
fore belongs to the class of radiomimetic poisons.
Chloroethylamines
Other drugs of this class of radiomimetic mitotic poisons are the
nitrogen mustards or chloroethylamines of which methyl-bis-(13-chlo-
roethyl)-amine, with code number HN2, is the best known example.
Up to the present these compounds have not been shown to be carcino-
genic, but I shall not be surprised if they are eventually found to be so.
During the war the pharmacology of the nitrogen mustards or chlo-
rethylamines was studied and their leukopenic action was demonstrated.
I admired the courage of the American workers"5 who first injected
substances of this type into human patients. There is no doubt that the
procedtire was justified and hundreds of patients suffering from
Hodgkin's disease must by now have benefited by treatment with these
drugs.
Our animal experiments have indicated the importance of adequate
dosage with substances of this type. If C3H mice with spontaneous
mammary tumours or a grafted lymphosarcoma, or rats with the
Walker carcinoma, are given divided doses of 0.2 mg. per kg. daily by
subcutaneous or intraperitoneal injection, very slight inhibition of
tumour growth is obtained. With the same total dosage given in massive
doses of 1 mg. per kg. every fifth day, complete inhibition of the growth
of the transplanted tumours and partial inhibition of spontaneous
mammary tumours in mice were obtained. The inhibition following a
single dose was temporary, lasting about one week in the case of the
Walker ratcarcinoma and up to two weeks in mice bearing spontaneous
tumours. Rats bearing the Walker carcinoma have been given weekly
injections ofHN2-starting with 1 mg. perkg. for the first three weeks,
and then reducing the dose to 0.5 mg. per kg. at weekly intervals.
Rats treated in this way have been kept alive for three months, when
all the control animals died within 21 days after grafting the tumour.
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Repeated injection of animals did not seem to make them ill, although
we have not looked for blood changes.
A curious side effect noticed in the injected mice was that the hair
was bleached at the site of injection. It appeared that subcutaneous in-
jection of the material caused a local inhibition of pigment formation
without having any effect on the growth of hair. This effect is similar
to that produced by radioactive material injected subcutaneously.
We have made some biochemical examinations of tissues from
animals dosed with HN2 (in collaboration with Miss E. Rhoden). The
Walker rat carcinoma tissue from animals dosed with 1 mg. per kg. of
HN2 had a reduced glycolysis for six days following a single treatment.
We could find no change in the tumour respiration as a result of the
injection. The nature of the inhibition of glycolysis has not been
examined further, but it is probably due to inhibition of hexokinase or
other phosphate-transferring enzymes concerned in glycolysis. It is
possible that the inhibition of mitosis is connected with enzymes of the
same type, either concerned in general metabolism or possibly in the
changes in the nucleic acids of the chromosomes.
Cytological examination of the tumour tissue by Dr. P. C. Koller
has shown that the inhibition of cell division is in prophase. The effect
is similar to that obtained with radiation or with urethane. Doses of
0.1 mg. per kg. of chloroethylamine give effects similar to doses of
urethane of 1 gm. perkg., so that chloroethylamine (HN2) is probably
more than 10,000 times as active as urethane, butboth chloroethylamine
and urethane may be described as radiomimetic poisons. Data in the
literature would indicate that a dose of 0.1 mg. per kg. of chlo-
roethylamine (HN2) is equivalent to an over-all body radiation of
about 50 r.
Chloroethylamines intreatment ofbronchogenic carinoma
Our clinical experience at the Royal Cancer Hospital in conjunction
with Dr. 0. H. Warwick has been largely in cases of bronchogenic car-
cinoma and our experience has been similar to thatobtained in America.
As animal experiments have shown that large single doses are more
effective than are divided doses, and because the total amount of dis-
comfort to the patient is decreased, by giving fewer but larger doses,
we have given two injections of methyl-bis-(t-chloroethyl)amine (0.2
mg. per kg.) on consecutive days, and recently we have given single
doses of 0.4 mg. per kg. In those cases in which a remission was noted,
the treatment was repeated as soon as possible after symptoms recurred.
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Nausea and vomiting for a period of 3 or 4 hours occur in almost
all patients and begin one to two hours after injection. Anorexia is
present in many cases for a period of 24 hours. The longest period of
reaction we have observed is 7 days, drowsiness and anorexia being
the main symptoms. The other adverse effects noted have been infre-
quent, and in no case has there been any cause for anxiety. With the
dosage we have used, the effects on the blood have not been marked.
These patients with lung cancer do not seem to develop the moderate
to severe leukopenia observed in cases of Hodgkin's disease similarly
treated. Hamorrhagic manifestations have not been observed in this
group of lung cases, nor has any significant change in hxmoglobin
been seen. The presence of fever and pleural exudate is not, in our
experience, a contra-indication to the use of the drug.
Over half of the patients have had relief from their most distressing
symptom. The effect on pain is remarkable in the majority of cases,
relief being experienced within 8 to 48 hours. The deep-seated pro-
topathic type of pain referred to as "being deep in the chest," is the
type most commonly relieved in contrast to the more localised pleural
type. Following treatment, cough is often decreased in severity and after
an initial period of several days when the sputum increases and is said
to "come up more easily," the amount may fall off rapidly in some cases
from 90 to 120 ml. to 15 ml. or nil. The sputum frequently changes in
character from purulent to colourless.
Although clinical remission of symptoms and observable beneficial
effects may be noted in over half the cases of bronchogenic carcinoma
treated, the remissions are only of short duration and the progression of
the disease does not seem to be altered materially. Only two of our
casescanbesaidtohavehadtheir lifeprolonged as a result of treatment.
The marked relief of symptoms observed in many patients has justified
the clinical use of the drug and further investigations are under way
using larger doses and combining the drug with radiation therapy.
Aromaticaminesintherapy
Early experiments on chemotherapy of cancer used the classical
method of testing dyes for their ability to stain tumour tissue when in-
jected intravenously, and revealed no dyes superior to trypan blue or
isamine blue as vital stains for tumours. In general, acid dyes with
aminonaphthol sulphonic acid residues acted as vital stains. Prontosil
soluble, the forerunner of the sulphonamides, was first described about
337YALE JOURNAL OF BIOLOGY AND MEDICINE
the time that the experiments were in progress. As prontosil contained
an aminonaphthol sulphonic acid residue, it was likely to stain tumour
tissue. When tested it acted as a tumour stain and on repeated injection
reduced the rate of growth of tumours in mice.4 Following this observa-
tion a number of sulphonamide derivatives were tested. Some of these
had growth-inhibitory action when given repeatedly in large doses; the
most effective was 4:4'-diaminodiphenylsulphoxide. The next step was
to test a number of diaminodiphenyl compounds, and it was soon seen
that the sulphur atom was not essential for activity. The best compound
of this series was 4:4'-diaminodiphenylether and we have been unable
to improve on this compound in this series.' Diaminodiphenylether
shows some specificity in that it inhibits the growth of spontaneous
mammary tumours in mice, but has no effect on grafted sarcomata or on
atransplanted lymphosarcoma. This substance has beengiven to patients
with mammary cancer in the form of the hydrochloride at the rate of 1
gm. per day for several months. The clinical results are not striking but
there is a suggestion that the treatment prolongs life.
Several of the examples of drugs which I have described show
specificity of action. Oestrogens are of value for cancer of the prostate,
urethane for both myeloid and lymphatic leukemia, chloroethylamines
for Hodgkin's disease and possibly bronchogenic carcinoma, and
diaminodiphenylether possibly for mammary cancer. Recently Snapper23
has obtained good results with stilbamidine in cases of myeloma. In
all these cases, the drugs show preferential action on tumours of a
particular site. This suggests that we might expect palliative remedies
for tumours of particular sites rather than a remedy for cancer in
general. For this reason, new drugs should be tested on a series of
different tumours rather than on one particular tumour. If a drug shows
specific action on a particular type of tumour it is less likely to damage
normal tissues.
Enzymepoisons
An obvious line of attack on tumours is to poison some essential
enzyme without damaging the host tissue. Much work has been carried
out on the metabolism and enzymes of cancer tissue, and such work is
still going forward, particularly in Dr. Greenstein's laboratory at
Bethesda. So far the main difference in enzyme content of normal and
of cancer tissue is in the catalase. Tumours are particularly deficient in
catalase which decomposes the hydrogen peroxide formed in many
biological oxidative processes. Hydrogen peroxide is toxic to cells, so
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that if it accumulated, the tumour cells should be killed. As tumours
have so little catalase, a general catalase poison might lead to accumu-
lation of hydrogen peroxide in the tumour tissue. The best known
catalase poisons are sodium azide and hydroxylamine. Azide is very toxic
but nitrosophenols, which are isomeric with quinone oximes or
hydroxylamine derivatives, can be given in small doses to animals. Of
a number of nitrosophenols tried, a-nitroso-,-naphthol was found to
inhibit tumour growth when given in tolerated doses. Such nitro-
sophenols are rather reactive substances, combining with metals such
as iron orcobalt, and the effects might be due to such an action.
Hemorrhagicagents
One class of substances which has been investigated includes those
whichproduce ahemorrhagic reaction in tumours. These belongmainly
to two types-the bacterial products which elicit the Shwartzman
phenomenon, and colchicine and related substances. These agents are
more toxic to tumour-bearing animals than to normal animals, and
they produce more effect in grafted tumours than in spontaneous or
induced tumours. The effect is associated with a pyrogen, and animal
and human tumours become resistant to later treatment.
Colchicine induces hemorrhage in tumours in addition to inhibiting
mitosis in metaphase. Colchicine is rather toxic for use in therapy, but
if a compound with a similar action on tumour tissue and with less
action on the alimentary tract were found, it should be of value.
Recently much work, has been carried out with podophyllin which
seems to have some of the effects of colchicine.
Methodsoftesting
Theusual lineofprogress inbiochemical research is first tofind some
biological property which can be affected by a preparation and then to
develop methods ofbiological assay which will give quantitative data on
biological effectiveness. In chemotherapy of cancer the methods of assay,
or what are called "screening tests," are still inadequate. There is reason
to expect remedies for cancer of particular sites rather than for cancer
in general. A drug with a specific action on a particular type of tumour
is less likely to damage other normal tissues, so that the limitation of
action may be a good thing. For this reason, potential therapeutic agents
for cancer should be tested against as wide a range of tumours as
possible. Difficulties arise in the establishment of suitable animal
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tumours particularly with animals of pure lines, and such animals are
of the greatest value for this work. We hope to have established a
series of tumours in mice including a mammary carcinoma, a sarcoma,
a hepatoma, a prostatic carcinoma, a lung tumour, a lymphosarcoma,
a leukoemia, and a gastric carcinoma. In addition to such tumours, well-
established transplanted tumours such as the Walker rat carcinoma are
of great value.
The methods used may depend upon measurement of growth or
of duration of life, or alternatively in histological, hxmatological, and
cytological changes caused by treatment. The increase in length of life
is the most practical criterion to use, but in the case of animals with
spontaneous tumours, the expected survival time of untreated animals
isveryvariable anddifficult to assess. In such cases thegrowth rate of the
tumour is taken into consideration with the body weight and general
health of the animal. With transplanted tumours, the extension of life
by treatment seems to be the most satisfactory guide, but in all cases,
histology and cytology can help in indicating the possible mechanism
ofdrug action.
There is little doubt that in the problem of cancer therapy we have
established the fact that some therapeutic effect against cancer can be
shown, so that some standards are established-the next steps should
be to establish methods of testing, using quantitative methods, and to
determine the mode of action of such agents as we have available for
the control of cancer growth. If good methods for assay of chemo-
therapeutic effectiveness can be established, then progress to rational
chemotherapy of cancer should be assured.
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